Table 1.

Demographics and baseline clinical parameters of the study population

Parameter	Total N = 229
Male gender, n (%)	171 (75)
Age, years	69 ± 11
Ischemic etiology, n (%)	125 (54)
Coronary artery disease	108 (47)
NYHA class
− Class I, n (%) − Class II, n (%) − Class III, n (%) − Class IV, n (%)	13 (6) 101 (44) 108 (47) 7 (3)
LV ejection fraction (%)	30 ± 8
AF history, n (%)	91 (40)
Diabetes, n (%)	75 (33)
COPD, n (%)	47 (20)
Chronic kidney disease, n (%)	85 (37)
Hypertension, n (%)	153 (67)
β‐Blocker use, n (%)	204 (89)
ACE‐inhibitor/ARB/ARNI use, n (%)	198 (86)
Diuretic use, n (%)	207 (90)
Antiarrhythmic use, n (%)	191 (28)
Ivabradine use, n (%)	26 (11)
CRT device, n (%)	197 (86)
Primary prevention, n (%)	199 (87)

Abbreviations: AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; LV, left ventricular; NYHA, New York Heart Association.